ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Varicella Attenuated Live Vaccine- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
Published Date: August 2025
|
Report Code: QYRE-Auto-14S616
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Varicella Attenuated Live Vaccine Market Insights and Forecast to 2028
BUY CHAPTERS

Varicella Attenuated Live Vaccine- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Code: QYRE-Auto-14S616
Report
August 2025
Pages:99
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Merck
GSK
BCHT
Keygen
Green Cross
Biken
Shanghai Institute
Shanghai Rongsheng Biotech
Changchun Changsheng Life Sciences Limited

Varicella Attenuated Live Vaccine- Market Size

The global market for Varicella Attenuated Live Vaccine was estimated to be worth US$ 2776 million in 2024 and is forecast to a readjusted size of US$ 3712 million by 2031 with a CAGR of 4.3% during the forecast period 2025-2031.

Varicella Attenuated Live Vaccine- Market

Varicella Attenuated Live Vaccine- Market

A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
For the major players of Varicella Attenuated Live Vaccine, Merck maintained its first place in the ranking in 2019, followed by BCHT, Shanghai Institute, GSK and Keygen. Top 5 players accounted for about 95% of the Global Varicella Attenuated Live Vaccine revenue market share in 2019.
The sales market for Varicella Attenuated Live Vaccine was divided into five geographic regions. Asia-Pacific occupied the largest sales market share with about 58% in 2019. It is followed by North America and Europe with about 18% and about 13% respectively, while other regions have smaller market.
This report aims to provide a comprehensive presentation of the global market for Varicella Attenuated Live Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Varicella Attenuated Live Vaccine by region & country, by Type, and by Application.
The Varicella Attenuated Live Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Varicella Attenuated Live Vaccine.
Market Segmentation

Scope of Varicella Attenuated Live Vaccine- Market Report

Report Metric Details
Report Name Varicella Attenuated Live Vaccine- Market
Forecasted market size in 2031 US$ 3712 million
CAGR 4.3%
Forecasted years 2025 - 2031
Segment by Type
  • Monovalent Vaccine
  • Combination Vaccine
Segment by Application
  • Kids Injection
  • Adults Injection
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Merck, BCHT, Shanghai Institute, GSK, Keygen, Green Cross, Biken, Shanghai Rongsheng Biotech, Changchun Changsheng Life Sciences Limited
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Varicella Attenuated Live Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Sales, revenue of Varicella Attenuated Live Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Sales, revenue of Varicella Attenuated Live Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

What is the Varicella Attenuated Live Vaccine- Market size in 2031?

Ans: The Varicella Attenuated Live Vaccine- Market size in 2031 will be US$ 3712 million.

What is the market share of major companies in Varicella Attenuated Live Vaccine- Market?

Ans: Top 5 players accounted for about 95% of the Global Varicella Attenuated Live Vaccine revenue market share in 2019.

What is the Varicella Attenuated Live Vaccine- Market share by region?

Ans: Asia-Pacific occupied the largest sales market share with about 58% in 2019.

Who are the main players in the Varicella Attenuated Live Vaccine- Market report?

Ans: The main players in the Varicella Attenuated Live Vaccine- Market are Merck, BCHT, Shanghai Institute, GSK, Keygen, Green Cross, Biken, Shanghai Rongsheng Biotech, Changchun Changsheng Life Sciences Limited

What are the Application segmentation covered in the Varicella Attenuated Live Vaccine- Market report?

Ans: The Applications covered in the Varicella Attenuated Live Vaccine- Market report are Kids Injection, Adults Injection

What are the Type segmentation covered in the Varicella Attenuated Live Vaccine- Market report?

Ans: The Types covered in the Varicella Attenuated Live Vaccine- Market report are Monovalent Vaccine, Combination Vaccine

1 Market Overview
1.1 Varicella Attenuated Live Vaccine Product Introduction
1.2 Global Varicella Attenuated Live Vaccine Market Size Forecast
1.2.1 Global Varicella Attenuated Live Vaccine Sales Value (2020-2031)
1.2.2 Global Varicella Attenuated Live Vaccine Sales Volume (2020-2031)
1.2.3 Global Varicella Attenuated Live Vaccine Sales Price (2020-2031)
1.3 Varicella Attenuated Live Vaccine Market Trends & Drivers
1.3.1 Varicella Attenuated Live Vaccine Industry Trends
1.3.2 Varicella Attenuated Live Vaccine Market Drivers & Opportunity
1.3.3 Varicella Attenuated Live Vaccine Market Challenges
1.3.4 Varicella Attenuated Live Vaccine Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Varicella Attenuated Live Vaccine Players Revenue Ranking (2024)
2.2 Global Varicella Attenuated Live Vaccine Revenue by Company (2020-2025)
2.3 Global Varicella Attenuated Live Vaccine Players Sales Volume Ranking (2024)
2.4 Global Varicella Attenuated Live Vaccine Sales Volume by Company Players (2020-2025)
2.5 Global Varicella Attenuated Live Vaccine Average Price by Company (2020-2025)
2.6 Key Manufacturers Varicella Attenuated Live Vaccine Manufacturing Base and Headquarters
2.7 Key Manufacturers Varicella Attenuated Live Vaccine Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Varicella Attenuated Live Vaccine
2.9 Varicella Attenuated Live Vaccine Market Competitive Analysis
2.9.1 Varicella Attenuated Live Vaccine Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Varicella Attenuated Live Vaccine Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Varicella Attenuated Live Vaccine as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Monovalent Vaccine
3.1.2 Combination Vaccine
3.2 Global Varicella Attenuated Live Vaccine Sales Value by Type
3.2.1 Global Varicella Attenuated Live Vaccine Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Varicella Attenuated Live Vaccine Sales Value, by Type (2020-2031)
3.2.3 Global Varicella Attenuated Live Vaccine Sales Value, by Type (%) (2020-2031)
3.3 Global Varicella Attenuated Live Vaccine Sales Volume by Type
3.3.1 Global Varicella Attenuated Live Vaccine Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Varicella Attenuated Live Vaccine Sales Volume, by Type (2020-2031)
3.3.3 Global Varicella Attenuated Live Vaccine Sales Volume, by Type (%) (2020-2031)
3.4 Global Varicella Attenuated Live Vaccine Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Kids Injection
4.1.2 Adults Injection
4.2 Global Varicella Attenuated Live Vaccine Sales Value by Application
4.2.1 Global Varicella Attenuated Live Vaccine Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Varicella Attenuated Live Vaccine Sales Value, by Application (2020-2031)
4.2.3 Global Varicella Attenuated Live Vaccine Sales Value, by Application (%) (2020-2031)
4.3 Global Varicella Attenuated Live Vaccine Sales Volume by Application
4.3.1 Global Varicella Attenuated Live Vaccine Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Varicella Attenuated Live Vaccine Sales Volume, by Application (2020-2031)
4.3.3 Global Varicella Attenuated Live Vaccine Sales Volume, by Application (%) (2020-2031)
4.4 Global Varicella Attenuated Live Vaccine Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Varicella Attenuated Live Vaccine Sales Value by Region
5.1.1 Global Varicella Attenuated Live Vaccine Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Varicella Attenuated Live Vaccine Sales Value by Region (2020-2025)
5.1.3 Global Varicella Attenuated Live Vaccine Sales Value by Region (2026-2031)
5.1.4 Global Varicella Attenuated Live Vaccine Sales Value by Region (%), (2020-2031)
5.2 Global Varicella Attenuated Live Vaccine Sales Volume by Region
5.2.1 Global Varicella Attenuated Live Vaccine Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Varicella Attenuated Live Vaccine Sales Volume by Region (2020-2025)
5.2.3 Global Varicella Attenuated Live Vaccine Sales Volume by Region (2026-2031)
5.2.4 Global Varicella Attenuated Live Vaccine Sales Volume by Region (%), (2020-2031)
5.3 Global Varicella Attenuated Live Vaccine Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Varicella Attenuated Live Vaccine Sales Value, 2020-2031
5.4.2 North America Varicella Attenuated Live Vaccine Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Varicella Attenuated Live Vaccine Sales Value, 2020-2031
5.5.2 Europe Varicella Attenuated Live Vaccine Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Varicella Attenuated Live Vaccine Sales Value, 2020-2031
5.6.2 Asia Pacific Varicella Attenuated Live Vaccine Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Varicella Attenuated Live Vaccine Sales Value, 2020-2031
5.7.2 South America Varicella Attenuated Live Vaccine Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Varicella Attenuated Live Vaccine Sales Value, 2020-2031
5.8.2 Middle East & Africa Varicella Attenuated Live Vaccine Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Varicella Attenuated Live Vaccine Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Varicella Attenuated Live Vaccine Sales Value
6.2.1 Key Countries/Regions Varicella Attenuated Live Vaccine Sales Value, 2020-2031
6.2.2 Key Countries/Regions Varicella Attenuated Live Vaccine Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Varicella Attenuated Live Vaccine Sales Value, 2020-2031
6.3.2 United States Varicella Attenuated Live Vaccine Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Varicella Attenuated Live Vaccine Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Varicella Attenuated Live Vaccine Sales Value, 2020-2031
6.4.2 Europe Varicella Attenuated Live Vaccine Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Varicella Attenuated Live Vaccine Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Varicella Attenuated Live Vaccine Sales Value, 2020-2031
6.5.2 China Varicella Attenuated Live Vaccine Sales Value by Type (%), 2024 VS 2031
6.5.3 China Varicella Attenuated Live Vaccine Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Varicella Attenuated Live Vaccine Sales Value, 2020-2031
6.6.2 Japan Varicella Attenuated Live Vaccine Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Varicella Attenuated Live Vaccine Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Varicella Attenuated Live Vaccine Sales Value, 2020-2031
6.7.2 South Korea Varicella Attenuated Live Vaccine Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Varicella Attenuated Live Vaccine Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Varicella Attenuated Live Vaccine Sales Value, 2020-2031
6.8.2 Southeast Asia Varicella Attenuated Live Vaccine Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Varicella Attenuated Live Vaccine Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Varicella Attenuated Live Vaccine Sales Value, 2020-2031
6.9.2 India Varicella Attenuated Live Vaccine Sales Value by Type (%), 2024 VS 2031
6.9.3 India Varicella Attenuated Live Vaccine Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Merck
7.1.1 Merck Company Information
7.1.2 Merck Introduction and Business Overview
7.1.3 Merck Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Merck Varicella Attenuated Live Vaccine Product Offerings
7.1.5 Merck Recent Development
7.2 BCHT
7.2.1 BCHT Company Information
7.2.2 BCHT Introduction and Business Overview
7.2.3 BCHT Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 BCHT Varicella Attenuated Live Vaccine Product Offerings
7.2.5 BCHT Recent Development
7.3 Shanghai Institute
7.3.1 Shanghai Institute Company Information
7.3.2 Shanghai Institute Introduction and Business Overview
7.3.3 Shanghai Institute Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Shanghai Institute Varicella Attenuated Live Vaccine Product Offerings
7.3.5 Shanghai Institute Recent Development
7.4 GSK
7.4.1 GSK Company Information
7.4.2 GSK Introduction and Business Overview
7.4.3 GSK Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 GSK Varicella Attenuated Live Vaccine Product Offerings
7.4.5 GSK Recent Development
7.5 Keygen
7.5.1 Keygen Company Information
7.5.2 Keygen Introduction and Business Overview
7.5.3 Keygen Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Keygen Varicella Attenuated Live Vaccine Product Offerings
7.5.5 Keygen Recent Development
7.6 Green Cross
7.6.1 Green Cross Company Information
7.6.2 Green Cross Introduction and Business Overview
7.6.3 Green Cross Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Green Cross Varicella Attenuated Live Vaccine Product Offerings
7.6.5 Green Cross Recent Development
7.7 Biken
7.7.1 Biken Company Information
7.7.2 Biken Introduction and Business Overview
7.7.3 Biken Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Biken Varicella Attenuated Live Vaccine Product Offerings
7.7.5 Biken Recent Development
7.8 Shanghai Rongsheng Biotech
7.8.1 Shanghai Rongsheng Biotech Company Information
7.8.2 Shanghai Rongsheng Biotech Introduction and Business Overview
7.8.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Offerings
7.8.5 Shanghai Rongsheng Biotech Recent Development
7.9 Changchun Changsheng Life Sciences Limited
7.9.1 Changchun Changsheng Life Sciences Limited Company Information
7.9.2 Changchun Changsheng Life Sciences Limited Introduction and Business Overview
7.9.3 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Offerings
7.9.5 Changchun Changsheng Life Sciences Limited Recent Development
8 Industry Chain Analysis
8.1 Varicella Attenuated Live Vaccine Industrial Chain
8.2 Varicella Attenuated Live Vaccine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Varicella Attenuated Live Vaccine Sales Model
8.5.2 Sales Channel
8.5.3 Varicella Attenuated Live Vaccine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
FEATURED COMPANIES
Merck
GSK
BCHT
Keygen
Green Cross
Biken
Shanghai Institute
Shanghai Rongsheng Biotech
Changchun Changsheng Life Sciences Limited
List of Tables
 Table 1. Varicella Attenuated Live Vaccine Market Trends
 Table 2. Varicella Attenuated Live Vaccine Market Drivers & Opportunity
 Table 3. Varicella Attenuated Live Vaccine Market Challenges
 Table 4. Varicella Attenuated Live Vaccine Market Restraints
 Table 5. Global Varicella Attenuated Live Vaccine Revenue by Company (2020-2025) & (US$ Million)
 Table 6. Global Varicella Attenuated Live Vaccine Revenue Market Share by Company (2020-2025)
 Table 7. Global Varicella Attenuated Live Vaccine Sales Volume by Company (2020-2025) & (K Doses)
 Table 8. Global Varicella Attenuated Live Vaccine Sales Volume Market Share by Company (2020-2025)
 Table 9. Global Market Varicella Attenuated Live Vaccine Price by Company (2020-2025) & (USD/Dose)
 Table 10. Key Manufacturers Varicella Attenuated Live Vaccine Manufacturing Base and Headquarters
 Table 11. Key Manufacturers Varicella Attenuated Live Vaccine Product Type
 Table 12. Key Manufacturers Time to Begin Mass Production of Varicella Attenuated Live Vaccine
 Table 13. Global Varicella Attenuated Live Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Varicella Attenuated Live Vaccine as of 2024)
 Table 15. Mergers & Acquisitions, Expansion Plans
 Table 16. Global Varicella Attenuated Live Vaccine Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
 Table 17. Global Varicella Attenuated Live Vaccine Sales Value by Type (2020-2025) & (US$ Million)
 Table 18. Global Varicella Attenuated Live Vaccine Sales Value by Type (2026-2031) & (US$ Million)
 Table 19. Global Varicella Attenuated Live Vaccine Sales Market Share in Value by Type (2020-2025)
 Table 20. Global Varicella Attenuated Live Vaccine Sales Market Share in Value by Type (2026-2031)
 Table 21. Global Varicella Attenuated Live Vaccine Sales Volume by Type: 2020 VS 2024 VS 2031 (K Doses)
 Table 22. Global Varicella Attenuated Live Vaccine Sales Volume by Type (2020-2025) & (K Doses)
 Table 23. Global Varicella Attenuated Live Vaccine Sales Volume by Type (2026-2031) & (K Doses)
 Table 24. Global Varicella Attenuated Live Vaccine Sales Market Share in Volume by Type (2020-2025)
 Table 25. Global Varicella Attenuated Live Vaccine Sales Market Share in Volume by Type (2026-2031)
 Table 26. Global Varicella Attenuated Live Vaccine Price by Type (2020-2025) & (USD/Dose)
 Table 27. Global Varicella Attenuated Live Vaccine Price by Type (2026-2031) & (USD/Dose)
 Table 28. Global Varicella Attenuated Live Vaccine Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
 Table 29. Global Varicella Attenuated Live Vaccine Sales Value by Application (2020-2025) & (US$ Million)
 Table 30. Global Varicella Attenuated Live Vaccine Sales Value by Application (2026-2031) & (US$ Million)
 Table 31. Global Varicella Attenuated Live Vaccine Sales Market Share in Value by Application (2020-2025)
 Table 32. Global Varicella Attenuated Live Vaccine Sales Market Share in Value by Application (2026-2031)
 Table 33. Global Varicella Attenuated Live Vaccine Sales Volume by Application: 2020 VS 2024 VS 2031 (K Doses)
 Table 34. Global Varicella Attenuated Live Vaccine Sales Volume by Application (2020-2025) & (K Doses)
 Table 35. Global Varicella Attenuated Live Vaccine Sales Volume by Application (2026-2031) & (K Doses)
 Table 36. Global Varicella Attenuated Live Vaccine Sales Market Share in Volume by Application (2020-2025)
 Table 37. Global Varicella Attenuated Live Vaccine Sales Market Share in Volume by Application (2026-2031)
 Table 38. Global Varicella Attenuated Live Vaccine Price by Application (2020-2025) & (USD/Dose)
 Table 39. Global Varicella Attenuated Live Vaccine Price by Application (2026-2031) & (USD/Dose)
 Table 40. Global Varicella Attenuated Live Vaccine Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
 Table 41. Global Varicella Attenuated Live Vaccine Sales Value by Region (2020-2025) & (US$ Million)
 Table 42. Global Varicella Attenuated Live Vaccine Sales Value by Region (2026-2031) & (US$ Million)
 Table 43. Global Varicella Attenuated Live Vaccine Sales Value by Region (2020-2025) & (%)
 Table 44. Global Varicella Attenuated Live Vaccine Sales Value by Region (2026-2031) & (%)
 Table 45. Global Varicella Attenuated Live Vaccine Sales Volume by Region (K Doses): 2020 VS 2024 VS 2031
 Table 46. Global Varicella Attenuated Live Vaccine Sales Volume by Region (2020-2025) & (K Doses)
 Table 47. Global Varicella Attenuated Live Vaccine Sales Volume by Region (2026-2031) & (K Doses)
 Table 48. Global Varicella Attenuated Live Vaccine Sales Volume by Region (2020-2025) & (%)
 Table 49. Global Varicella Attenuated Live Vaccine Sales Volume by Region (2026-2031) & (%)
 Table 50. Global Varicella Attenuated Live Vaccine Average Price by Region (2020-2025) & (USD/Dose)
 Table 51. Global Varicella Attenuated Live Vaccine Average Price by Region (2026-2031) & (USD/Dose)
 Table 52. Key Countries/Regions Varicella Attenuated Live Vaccine Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
 Table 53. Key Countries/Regions Varicella Attenuated Live Vaccine Sales Value, (2020-2025) & (US$ Million)
 Table 54. Key Countries/Regions Varicella Attenuated Live Vaccine Sales Value, (2026-2031) & (US$ Million)
 Table 55. Key Countries/Regions Varicella Attenuated Live Vaccine Sales Volume, (2020-2025) & (K Doses)
 Table 56. Key Countries/Regions Varicella Attenuated Live Vaccine Sales Volume, (2026-2031) & (K Doses)
 Table 57. Merck Company Information
 Table 58. Merck Introduction and Business Overview
 Table 59. Merck Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 60. Merck Varicella Attenuated Live Vaccine Product Offerings
 Table 61. Merck Recent Development
 Table 62. BCHT Company Information
 Table 63. BCHT Introduction and Business Overview
 Table 64. BCHT Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 65. BCHT Varicella Attenuated Live Vaccine Product Offerings
 Table 66. BCHT Recent Development
 Table 67. Shanghai Institute Company Information
 Table 68. Shanghai Institute Introduction and Business Overview
 Table 69. Shanghai Institute Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 70. Shanghai Institute Varicella Attenuated Live Vaccine Product Offerings
 Table 71. Shanghai Institute Recent Development
 Table 72. GSK Company Information
 Table 73. GSK Introduction and Business Overview
 Table 74. GSK Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 75. GSK Varicella Attenuated Live Vaccine Product Offerings
 Table 76. GSK Recent Development
 Table 77. Keygen Company Information
 Table 78. Keygen Introduction and Business Overview
 Table 79. Keygen Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 80. Keygen Varicella Attenuated Live Vaccine Product Offerings
 Table 81. Keygen Recent Development
 Table 82. Green Cross Company Information
 Table 83. Green Cross Introduction and Business Overview
 Table 84. Green Cross Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 85. Green Cross Varicella Attenuated Live Vaccine Product Offerings
 Table 86. Green Cross Recent Development
 Table 87. Biken Company Information
 Table 88. Biken Introduction and Business Overview
 Table 89. Biken Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 90. Biken Varicella Attenuated Live Vaccine Product Offerings
 Table 91. Biken Recent Development
 Table 92. Shanghai Rongsheng Biotech Company Information
 Table 93. Shanghai Rongsheng Biotech Introduction and Business Overview
 Table 94. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 95. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Offerings
 Table 96. Shanghai Rongsheng Biotech Recent Development
 Table 97. Changchun Changsheng Life Sciences Limited Company Information
 Table 98. Changchun Changsheng Life Sciences Limited Introduction and Business Overview
 Table 99. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 100. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Offerings
 Table 101. Changchun Changsheng Life Sciences Limited Recent Development
 Table 102. Key Raw Materials Lists
 Table 103. Raw Materials Key Suppliers Lists
 Table 104. Varicella Attenuated Live Vaccine Downstream Customers
 Table 105. Varicella Attenuated Live Vaccine Distributors List
 Table 106. Research Programs/Design for This Report
 Table 107. Key Data Information from Secondary Sources
 Table 108. Key Data Information from Primary Sources


List of Figures
 Figure 1. Varicella Attenuated Live Vaccine Product Picture
 Figure 2. Global Varicella Attenuated Live Vaccine Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Global Varicella Attenuated Live Vaccine Sales Value (2020-2031) & (US$ Million)
 Figure 4. Global Varicella Attenuated Live Vaccine Sales Volume (2020-2031) & (K Doses)
 Figure 5. Global Varicella Attenuated Live Vaccine Sales Price (2020-2031) & (USD/Dose)
 Figure 6. Varicella Attenuated Live Vaccine Report Years Considered
 Figure 7. Global Varicella Attenuated Live Vaccine Players Revenue Ranking (2024) & (US$ Million)
 Figure 8. Global Varicella Attenuated Live Vaccine Players Sales Volume Ranking (2024) & (K Doses)
 Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Varicella Attenuated Live Vaccine Revenue in 2024
 Figure 10. Varicella Attenuated Live Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 11. Monovalent Vaccine Picture
 Figure 12. Combination Vaccine Picture
 Figure 13. Global Varicella Attenuated Live Vaccine Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
 Figure 14. Global Varicella Attenuated Live Vaccine Sales Value Market Share by Type, 2024 & 2031
 Figure 15. Global Varicella Attenuated Live Vaccine Sales Volume by Type (2020 VS 2024 VS 2031) & (K Doses)
 Figure 16. Global Varicella Attenuated Live Vaccine Sales Volume Market Share by Type, 2024 & 2031
 Figure 17. Global Varicella Attenuated Live Vaccine Price by Type (2020-2031) & (USD/Dose)
 Figure 18. Product Picture of Kids Injection
 Figure 19. Product Picture of Adults Injection
 Figure 20. Global Varicella Attenuated Live Vaccine Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
 Figure 21. Global Varicella Attenuated Live Vaccine Sales Value Market Share by Application, 2024 & 2031
 Figure 22. Global Varicella Attenuated Live Vaccine Sales Volume by Application (2020 VS 2024 VS 2031) & (K Doses)
 Figure 23. Global Varicella Attenuated Live Vaccine Sales Volume Market Share by Application, 2024 & 2031
 Figure 24. Global Varicella Attenuated Live Vaccine Price by Application (2020-2031) & (USD/Dose)
 Figure 25. North America Varicella Attenuated Live Vaccine Sales Value (2020-2031) & (US$ Million)
 Figure 26. North America Varicella Attenuated Live Vaccine Sales Value by Country (%), 2024 VS 2031
 Figure 27. Europe Varicella Attenuated Live Vaccine Sales Value, (2020-2031) & (US$ Million)
 Figure 28. Europe Varicella Attenuated Live Vaccine Sales Value by Country (%), 2024 VS 2031
 Figure 29. Asia Pacific Varicella Attenuated Live Vaccine Sales Value, (2020-2031) & (US$ Million)
 Figure 30. Asia Pacific Varicella Attenuated Live Vaccine Sales Value by Region (%), 2024 VS 2031
 Figure 31. South America Varicella Attenuated Live Vaccine Sales Value, (2020-2031) & (US$ Million)
 Figure 32. South America Varicella Attenuated Live Vaccine Sales Value by Country (%), 2024 VS 2031
 Figure 33. Middle East & Africa Varicella Attenuated Live Vaccine Sales Value, (2020-2031) & (US$ Million)
 Figure 34. Middle East & Africa Varicella Attenuated Live Vaccine Sales Value by Country (%), 2024 VS 2031
 Figure 35. Key Countries/Regions Varicella Attenuated Live Vaccine Sales Value (%), (2020-2031)
 Figure 36. Key Countries/Regions Varicella Attenuated Live Vaccine Sales Volume (%), (2020-2031)
 Figure 37. United States Varicella Attenuated Live Vaccine Sales Value, (2020-2031) & (US$ Million)
 Figure 38. United States Varicella Attenuated Live Vaccine Sales Value by Type (%), 2024 VS 2031
 Figure 39. United States Varicella Attenuated Live Vaccine Sales Value by Application (%), 2024 VS 2031
 Figure 40. Europe Varicella Attenuated Live Vaccine Sales Value, (2020-2031) & (US$ Million)
 Figure 41. Europe Varicella Attenuated Live Vaccine Sales Value by Type (%), 2024 VS 2031
 Figure 42. Europe Varicella Attenuated Live Vaccine Sales Value by Application (%), 2024 VS 2031
 Figure 43. China Varicella Attenuated Live Vaccine Sales Value, (2020-2031) & (US$ Million)
 Figure 44. China Varicella Attenuated Live Vaccine Sales Value by Type (%), 2024 VS 2031
 Figure 45. China Varicella Attenuated Live Vaccine Sales Value by Application (%), 2024 VS 2031
 Figure 46. Japan Varicella Attenuated Live Vaccine Sales Value, (2020-2031) & (US$ Million)
 Figure 47. Japan Varicella Attenuated Live Vaccine Sales Value by Type (%), 2024 VS 2031
 Figure 48. Japan Varicella Attenuated Live Vaccine Sales Value by Application (%), 2024 VS 2031
 Figure 49. South Korea Varicella Attenuated Live Vaccine Sales Value, (2020-2031) & (US$ Million)
 Figure 50. South Korea Varicella Attenuated Live Vaccine Sales Value by Type (%), 2024 VS 2031
 Figure 51. South Korea Varicella Attenuated Live Vaccine Sales Value by Application (%), 2024 VS 2031
 Figure 52. Southeast Asia Varicella Attenuated Live Vaccine Sales Value, (2020-2031) & (US$ Million)
 Figure 53. Southeast Asia Varicella Attenuated Live Vaccine Sales Value by Type (%), 2024 VS 2031
 Figure 54. Southeast Asia Varicella Attenuated Live Vaccine Sales Value by Application (%), 2024 VS 2031
 Figure 55. India Varicella Attenuated Live Vaccine Sales Value, (2020-2031) & (US$ Million)
 Figure 56. India Varicella Attenuated Live Vaccine Sales Value by Type (%), 2024 VS 2031
 Figure 57. India Varicella Attenuated Live Vaccine Sales Value by Application (%), 2024 VS 2031
 Figure 58. Varicella Attenuated Live Vaccine Industrial Chain
 Figure 59. Varicella Attenuated Live Vaccine Manufacturing Cost Structure
 Figure 60. Channels of Distribution (Direct Sales, and Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

Global Varicella Attenuated Live Vaccination Market Research Report 2025
Varicella Virus Attenuated Live Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Varicella Virus Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Chickenpox Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Live Herpes Zoster Vaccine Market Research Report 2024
Global Varicella Live Vaccine Market Insights Forecast to 2030
Global Varicella Vaccination Market Research Report 2025
Global Live Attenuated Vaccine for Chickenpox Market Research Report 2025
Global Varicella Vaccine Sales Market Report Competitive Analysis and Regional Opportunities 2025 2031
Global Poultry Live Attenuated Vaccine Market Research Report 2024
Global Live Attenuated Varicella Vaccine Market Research Report 2025
Live Attenuated Herpes Zoster Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Live Attenuated Vaccines for Pets Market Research Report 2025
Global Live Attenuated Polio Vaccine Market Research Report 2024
Live Attenuated Japanese Encephalitis Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Chickenpox Varicella Vaccine Market
Global Live Attenuated Rotavirus Vaccine Market Research Report 2024
Global Live Attenuated Vaccine for Pig Market Research Report 2024
Live and Attenuated Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Nasal Spray Live Attenuated Vaccine Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions